Reinventing Clinical Trials
This article was originally published in RPM Report
The clincal trial process needs to be modernized for the good of drug development.
You may also be interested in...
Despite a setback presented by a small micro-dosing trial in the UK, FDA says its "Phase Zero" program has appropriate safeguards in place and should be pursued by biopharmaceutical companies.
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.